Equities Analysts Offer Predictions for MNPR Q2 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Investment analysts at Brookline Capital Management raised their Q2 2025 earnings estimates for Monopar Therapeutics in a note issued to investors on Tuesday, May 13th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will post earnings of ($0.55) per share for the quarter, up from their prior forecast of ($0.81). The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. Brookline Capital Management also issued estimates for Monopar Therapeutics’ Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($1.06) EPS and FY2025 earnings at ($2.53) EPS.

Other analysts have also issued reports about the company. Piper Sandler restated an “overweight” rating and issued a $76.00 target price on shares of Monopar Therapeutics in a research note on Wednesday, March 19th. Jones Trading restated a “hold” rating on shares of Monopar Therapeutics in a research report on Wednesday, April 2nd. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Monopar Therapeutics in a research report on Tuesday, April 1st.

Monopar Therapeutics Stock Performance

Shares of MNPR opened at $39.55 on Friday. The company has a market cap of $241.85 million, a price-to-earnings ratio of -20.08 and a beta of 1.11. The stock has a fifty day moving average price of $37.34 and a two-hundred day moving average price of $31.48. Monopar Therapeutics has a 52-week low of $1.72 and a 52-week high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR) last posted its earnings results on Tuesday, May 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.27.

Insider Activity

In other Monopar Therapeutics news, major shareholder Tactic Pharma Llc sold 33,334 shares of the firm’s stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the sale, the insider now directly owns 822,255 shares in the company, valued at approximately $28,778,925. This trade represents a 3.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 20.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. AlphaQuest LLC bought a new stake in Monopar Therapeutics in the 1st quarter valued at $44,000. JPMorgan Chase & Co. acquired a new stake in shares of Monopar Therapeutics in the 4th quarter valued at about $45,000. Gerber LLC bought a new stake in shares of Monopar Therapeutics in the first quarter valued at about $204,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Monopar Therapeutics during the first quarter worth about $328,000. Finally, Geode Capital Management LLC grew its holdings in shares of Monopar Therapeutics by 174.4% during the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock worth $849,000 after buying an additional 24,530 shares in the last quarter. Institutional investors and hedge funds own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.